Founded in the United States, Imricor Medical Systems is dedicated to advancing the treatment of cardiac arrhythmias through the development of MRI-compatible electrophysiology tools. The company's core mission is to transform cardiac ablation procedures by integrating them into the MRI environment, thereby enhancing precision and patient outcomes. Imricor’s innovative products are designed for use in interventional cardiac magnetic resonance (iCMR) settings, targeting a niche market within the broader medical device industry.

Notable figures associated with Imricor include its CEO, who has shared insights on the company's founding and future directions through platforms like Equity Mates. The company has achieved significant milestones, including receiving regulatory approval from the Saudi Food and Drug Authority. Imricor's impact lies in its pioneering approach to cardiac ablation, potentially setting new standards in electrophysiology and improving the quality of care for patients with cardiac arrhythmias.